Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

FARESTON- toremifene citrate tablet

Patient Information

Vaginal bleeding has been reported in patients using FARESTON. Patients should be informed about this and instructed to contact their physician if such bleeding or other gynecological symptoms (changes in vaginal discharge, pelvic pain or pressure) occur. Patients should have a gynecological examination prior to initiation of therapy and at regular intervals while on therapy.

Liver disorders including transaminits grade 3 and 4, hyperbilirubinemia with jaundice have been reported in patients using FARESTON. Patients should have liver function tests performed periodically while on therapy.

FARESTON may harm the fetus and increase the risk for pregnancy loss[seeWarnings and Precautions (5.7)andUse in Specific Populations (8.1)].

Premenopausal women using FARESTON should use nonhormonal contraception during treatment and should be apprised of the potential hazard to the fetus should pregnancy occur[seeWarnings and Precautions (5.8)].

Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia and instructed to contact their physician for further assessment if such signs or symptoms occur.

Patients who must take medications known to prolong the QT interval, or potent CYP3A4 inhibitors, should be informed of the effect of toremifene on QT interval. Toremifene has been shown to prolong the QTc interval in a dose-related manner[seeBoxed Warning, Warnings and Precautions (5.1), and Clinical Pharmacology (12.2)].

Specific interactions with foods that inhibit CYP3A4, including grapefruit juice, have not been studied but may increase toremifene concentrations. Patients should avoid grapefruit products and other foods that are known to inhibit CYP3A4 during FARESTON treatment.

Certain other medicines, including over-the-counter medications or herbal supplements (such as St. John's Wort) and toremifene, can reduce concentrations of co-administered drugs[see Drug Interactions (7.3)].

Distributed by
Kyowa Kirin, Inc.
Bedminster, NJ 07921, USA
Product covered by Orion Product Patents and related patent numbers
2017 Kyowa Kirin, Inc.
All rights reserved.

Rev. 05/2017

Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: